Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
- Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
- With product now available, today we are providing initial PEMGARDA net product revenue guidance in the range of $150 million to $200 million for the full year 2024.
- For additional information about PEMGARDA, please see the full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.
- Those who plan on participating are advised to join 15 minutes prior to the start time.